Several small-molecule inhibitors, including GLUT inhibitors (e.g., fasentin, WZB117) and nicotinamide phosphoribosyltransferase inhibitors (e.g., GMX1778, STF-31), impair tumor cell proliferation by disrupting glucose uptake and energy production [148,149]. Here, SLC2A1 is linked to neoplasm.